GEN uncovers seven biopharma-related trends based on interviews with experts and other industry stakeholders, as well as ...

This was the stock's third consecutive day of gains.

After years of controversy, stem cells are on the cusp of cures for conditions like epilepsy and type 1 diabetes.

Fintel reports that on January 3, 2025, Raymond James downgraded their outlook for Vertex (NasdaqGM:VERX) from Outperform to Market Perform. Analyst Price Forecast Suggests 8.59% Upside As of December ...

Vertex (VERX – Research Report) received a Hold rating and price target from Raymond James analyst Alexander Sklar today. The company’s ...

A member of the IBD Big Cap 20, Vertex is a top stock to consider after impressive growth last year. VERX stock could present ...

The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...

Fintel reports that on December 31, 2024, DA Davidson initiated coverage of Vertex (NasdaqGM:VERX) with a Buy recommendation.

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $57.33, along ...

Vertex (VERX) has received a new Buy rating, initiated by D.A. Davidson analyst, Will Jellison.Don't Miss Our New Year's Offers:Discover the ...